Healthcare company PDL BioPharma has announced that it will soon gain royalties from sales of Sanofi’s Cerdelga (eliglustat) drug, used to treat Gaucher disease.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
PDL BioPharma, Cerdelga, Sanofi, Genzyme, University of Michigan
